# Gemcitabine and Cisplatin With Ivosidenib or Pemigatinib for the Treatment of Unresectable or Metastatic Cholangiocarcinoma

> **NCT04088188** · PHASE1 · TERMINATED · sponsor: **Academic and Community Cancer Research United** · enrollment: 8 (actual)

## Conditions studied

- Advanced Cholangiocarcinoma
- Metastatic Cholangiocarcinoma
- Unresectable Cholangiocarcinoma

## Interventions

- **DRUG:** Cisplatin
- **DRUG:** Gemcitabine
- **DRUG:** Ivosidenib
- **DRUG:** Pemigatinib

## Key facts

- **NCT ID:** NCT04088188
- **Lead sponsor:** Academic and Community Cancer Research United
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-01-25
- **Primary completion:** 2023-12-01
- **Final completion:** 2023-12-01
- **Target enrollment:** 8 (ACTUAL)
- **Why stopped:** Low accrual
- **Last updated:** 2024-05-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04088188

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04088188, "Gemcitabine and Cisplatin With Ivosidenib or Pemigatinib for the Treatment of Unresectable or Metastatic Cholangiocarcinoma". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04088188. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*